60 results
Page 3 of 3
424B5
qi5n8umr
20 Feb 20
Prospectus supplement for primary offering
9:54pm
8-K
EX-10.1
3btfse0ldito4t938
20 Feb 20
Entry into a Material Definitive Agreement
9:50pm
8-K
EX-1.1
calbpwu9k9z2wul1e7u
20 Feb 20
Entry into a Material Definitive Agreement
9:50pm
8-K
af180a7b6el
19 Feb 20
Results of Operations and Financial Condition
5:11pm
424B5
bvvd1nr77u0gn3uzm87
19 Feb 20
Prospectus supplement for primary offering
5:07pm
424B5
bcm 7zzqn2kymy7
28 Sep 19
Prospectus supplement for primary offering
1:42am
8-K
EX-1.1
orrpx2ya8tuy4h
27 Sep 19
Other Events
5:31pm
424B5
bp36d0ty lg9at4fnbf
25 Sep 19
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
0r3xz2zw32rne4
22 Jul 19
Regulation FD Disclosure
9:29am
8-K
EX-1.1
suwc67mwc4 7w3
20 May 19
Entry into a Material Definitive Agreement
9:28am
DEF 14A
9qxpbpoy8q st08iwxf5
1 Apr 19
Definitive proxy
5:20pm
8-K
EX-99.1
2fan d7zwa
12 Mar 19
Other Events
5:21pm
10-K
rx944 43vly6pm
12 Mar 19
Annual report
12:00am
8-K
EX-99.1
elm7twh 7ayoqd
4 Feb 19
Other Events
5:03pm
8-K
EX-99.2
fdb4 w8zo2e
3 Jan 19
Regulation FD Disclosure
4:16pm
8-K
EX-99.1
n4b ldhgcg4jh7ymco5
14 Nov 18
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia PatientsĀ Supporting BXCL501 Clinical Development
8:44am